For Healthcare Professionals

Study to Evaluate the Efficacy of Uproleselan in Combination With Chemotherapy in Chinese Patients With R/R AML


About the study

This bridging study will evaluate the efficacy of uproleselan, a specific E-selectin antagonist, in combination with chemotherapy to treat Chinese relapsed/refractory AML patients, compared to chemotherapy alone. The safety of uproleselan when given with chemotherapy will also be investigated in patients with relapsed/refractory AML

Who can take part

You may be eligible to participate in the study if you meet the following criteria:


Inclusion Criteria:

  1. ≥18 years and ≤75 years in age
  2. AML diagnosed with ≥20% myeloid marrow blasts or peripheral blood blasts per WHO criteria(2008) at the time of initial diagnosis

For refractory AML, only cytarabine/daunorubicin(or Idarubicin) as can be applied repeatedly(maximal twice) as induction, no other chemotherapy are allowed to be applied Venatoclax /hypomethylation drug [HMA] can be used before and after chemotherapy.

  1. For relapse AML, it must be the first or second relapse, and remain untreated.
  2. Certain regimens (Venatoclax/HMA, Venetoclax/LDAC, HMA single agent) and FLT3 inhibitors, tyrosine kinase inhibitors, IDH1/IDH2 inhibitors or similar targeted inhibitors used alone are not considered cytotoxic chemotherapy are allowed.
  3. No more than one prior stem cell transplant
  4. Has not received the chemotherapy regimen to be used for induction on this trial
  5. Is considered medically eligible to receive the chemotherapy regimen to be used for induction on this trial


Exclusion Criteria:

  1. Patients with acute promyelocytic leukemia
  2. Acute leukemia of ambiguous lineage (biphenotypic leukemia)
  3. Chronic myeloid leukemia with myeloid blast crisis
  4. Active signs or symptoms of CNS involvement by malignancy (No lumbar puncture required)
  5. Prior use of G-CSF, CM-CSF or plerixafor within 7 days of dosing.
  6. Stem cell transplantation ≤4 months prior to dosing.
  7. Any immunotherapy or radiotherapy therapy within 28 days of dosing; any other experimental therapy or chemotherapy within 14 days of dosing
  8. Inadequate organ function.
  9. Abnormal liver function.
  10. Known active infection with hepatitis A, B, or C, or human immunodeficiency virus.
  11. Moderate kidney dysfunction (glomerular filtration rate <45 mL/min).
  12. Uncontrolled acute life-threatening bacterial, viral, or fungal infection.
  13. Clinically significant cardiovascular disease.
  14. Major surgery within 4 weeks of dosing.
pin location

Study Locations

Enter your ZIP code/Postal code/PIN code to locate study sites near you:

How to Apply

Contact the study center to learn if this study is a good match for you.

Study’s details


Relapsed/Refractory AML

Age (in years)

18 - 75


Phase 3

Participants needed


Est. Completion Date

Feb 29, 2024

Treatment type



Apollomics Inc. identifier


Study number


Understanding Clinical Trials

Get answers to your questions about clinical trials.What is a clinical research?What does taking part in clinical trials involve?What should I ask the trial doctor?


Sign up to save your favorites, 
receive newsletters, resources, and alerts 
about clinical trials related to your conditions of interest.